AOD-9604 5mg

Product Background

AOD-9604 is a synthetic 16-amino-acid peptide fragment corresponding to residues 176–191 of the C-terminus of human growth hormone (hGH), with the addition of an N-terminal tyrosine. It was developed in the 1990s by researchers at Monash University and later commercialized by Metabolic Pharmaceuticals in Australia, who investigated its potential as an anti-obesity therapeutic. The compound was designed to isolate the lipolytic (fat-mobilizing) properties of hGH while excluding the growth-promoting and insulin-resistance effects associated with the full hormone. AOD-9604 advanced through Phase II clinical trials for obesity in the mid-2000s, and while it did not achieve marketing approval as a weight-loss therapeutic, it received Generally Recognized as Safe (GRAS) status in the United States in 2014 and has remained a compound of scientific interest in metabolic research.

About the Product

Each vial contains 5 mg of AOD-9604 supplied as a lyophilized white powder at ≥99% purity, with 10 vials per package. The compound must be reconstituted in bacteriostatic or sterile water prior to use in any laboratory protocol. AOD-9604 is supplied for controlled research environments where consistent dosing of a stable hGH-fragment analogue is required.

Applications

• Investigations of lipolysis and free fatty acid release in adipocyte cultures
• Studies of fat oxidation and energy expenditure in animal models
• Body composition research in preclinical obesity models
• Research into cartilage and joint repair mechanisms (emerging area)
• Comparative studies versus full-length growth hormone and GLP-1 receptor agonists
• Studies of metabolic signaling pathways involved in lipid metabolism